43 results about "Omarigliptin" patented technology

The invention relates to novel omarigliptin salt and crystal form products of the omarigliptin salt, and belongs to the technical field of pharmaceutical chemicrystallization. Compared with existing omarigliptin crystal form products, the omarigliptin salt and the crystal form products of the omarigliptin salt have the advantages of being better in crystal form product stability and solubility, higher in dissolving rate and the like, the bioavailability of medicine can be improved, and the omarigliptin salt and the crystal form products of the omarigliptin salt are better suitable for an application of a solid preparation. The invention also relates to the omarigliptin salt, a preparing method of the crystal form products of the omarigliptin salt, a pharmaceutical composition of the omarigliptin salt and applications of the omarigliptin salt to medicine for treating type 2 diabetes mellitus.

The invention relates to a combination product of a limonin compound, pharmaceutically-acceptable derivatives, esters, stereoisomers, salts or prodrugs thereof and dipeptidyl peptidase-4(DPP-4) inhibitors such as sitagliptin, saxagliptin, vildagliptin, linagliptin, alogliptin, trelagliptin and omarigliptin. The invention further relates to application of the combination product in treating and / orpreventing diseases related to diabetes.

The invention discloses a pharmaceutical composition taking metformin or pharmaceutical salts thereof and omarigliptin or pharmaceutical salts thereof as active ingredients. Pharmacological research results show that the pharmaceutical composition of metformin hydrochloride and omarigliptin hydrochloride can improve the pancreatic islet form of a test animal, effectively reduce the blood glucose level of a diabetic model animal and improve glucose tolerance; the hypoglycemic effect is dose-dependent; and furthermore, the hypoglycemic effect is rapid, stable and lasting.

An improved process for the preparation of a key intermediate for the synthesis of the active ingredient Omarigliptin is provided. The key intermediate is a compound having the following formula (I)wherein R1 is propargyl or allyl group and P is an amine protecting group. The compound of formula (I) is prepared by converting a compound of formula (IV)by an amination reaction to a compound of formula (III),which is then protected to provide a compound of formula (II),which is then alkylated to provide the compound of formula (I).

The invention relates to novel omarigliptin salt and crystal form products of the omarigliptin salt, and belongs to the technical field of pharmaceutical chemicrystallization. Compared with existing omarigliptin crystal form products, the omarigliptin salt and the crystal form products of the omarigliptin salt have the advantages of being better in crystal form product stability and solubility, higher in dissolving rate and the like, the bioavailability of medicine can be improved, and the omarigliptin salt and the crystal form products of the omarigliptin salt are better suitable for an application of a solid preparation. The invention also relates to the omarigliptin salt, a preparing method of the crystal form products of the omarigliptin salt, a pharmaceutical composition of the omarigliptin salt and applications of the omarigliptin salt to medicine for treating type 2 diabetes mellitus.

The invention discloses a quinoline derivative or pharmacologically acceptable salt shown as a formula I (The formula is shown in the description), wherein R1, R2, R3 and R4 are respectively selectedfrom H or CH3. The compound listed in an in vitro DPP-4 enzyme inhibition test on the inhibition activity of DPP-4 is between Sitagliptin and omarigliptin. The quinoline derivative shown as the formula I disclosed by the invention is a DPP-4 inhibitor with a novel structure type, and the characteristics of the quinoline derivative in pharmacological toxicology and pharmacokinetics deserve more in-depth study, so that drugs used for treating and / or preventing non-insulin-dependent diabetes, hyperglycemia or insulin resistance can be obtained.

The invention provides a DP-IV inhibitor drug composition which comprises Omarigliptin and reducing sugar. According to the DP-IV inhibitor drug composition, the prejudice is overcome, an Omarigliptindomestic preparation is provided, the cost is low, the digestion is consistent with that of the original drug, and the stability is higher than that of the original drug.

The invention discloses Omarigliptin and a preparation method of an intermediate of the Omarigliptin, and provides a preparation method of an Omarigliptin intermediate I. The preparation method comprises the following step: enabling a compound II and a compound III to undergo a condensation reaction in a polar aprotic organic solvent in the presence of lewis acid and sodium borohydride acetate to obtain the Omarigliptin intermediate I. The preparation method disclosed by the invention has the advantages of simple and safe operation, no need of special purification equipment, short reaction time, fewer by products, high yield and simple post treatment operation; column chromatography separating operation in a post treatment process is avoided; a prepared product is high in purity, the optical purity is greater than or equal to 99,9 percent, the purity of a related substance is greater than or equal to 98.5 percent, and the purities of all impurities are smaller than or equal to 0.5 percent separately; the preparation method is low in production cost and is suitable for industrial production. In addition, according to the Omarigliptin prepared from the Omarigliptin intermediate I obtained by adopting the preparation method disclosed by the invention, the purity is greater than or equal to 99.5 percent, the purities of all the impurities are smaller than or equal to 0.1 percent separately, and the standards of crude drugs are reached. (The formula is shown in the description).

The invention provides an omarigliptin intermediate preparation method. The omarigliptin intermediate preparation method comprises the step of mixing a compound I with a catalyzing enzyme, and reacting to obtain an omarigliptin intermediate. The omarigliptin intermediate preparation method has the beneficial effects that the cost of raw materials is reduced; the problem in the prior art that isomer byproducts are generated during preparation of the omarigliptin intermediate and cannot be utilized is effectively solved; the yield and atom economy are increased; and the omarigliptin intermediate preparation method is simple in operation, mild in conditions, environment-friendly and suitable for industrial production.

The invention discloses a quinoline derivative represented by formula I, or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, and R5 are used for representing groups independently selected from H or CF3. In in vitro DPP-4 enzyme inhibition experiment, the IC50 value of the quinoline derivative on DPP-4 is lower than that of omarigliptin and sitagliptin. It is shown that the quinoline derivative possesses excellent DPP-4 inhibition activity, and can be used in preparation of drug used for treating and / or preventing non-insulin-dependent diabetes, hyperglycemia, or insulin resistance.

The invention discloses a novel synthesis method for preparing a chiral intermediate of omarigliptin. The method disclosed by the invention comprises the following steps: taking crotonyl chloride and (S)-4-benzyl-2-oxazolidone as starting raw materials and carrying out amidation, alder condensation, hydrolysis, Curtius rearrangement, Boc addition and ring opening to obtain the chiral intermediate (VI). The preparation method disclosed by the invention has the advantages of relatively short route, relatively low cost, easiness for obtaining the raw materials and relatively high yield so that the preparation method is suitable for industrial production. A formula is shown in the description.

The invention discloses a compound shown in a formula I or pharmaceutically acceptable salts of the compound; the formula I is described in the description, wherein R1, R2, R3, R4 and R5 are independently selected from H or CF3. The IC50 values, for the dipeptidyl peptidase-IV (DPP-4), of compounds listed in in-vitro DPP-4 enzyme inhibition tests are less than those of omarigliptin and Sitagliptin. The compound provided by the invention is proved to have better DPP-4 inhibitory activity, thus being used as a medicine for treating and / or preventing non-insulin-dependent diabetes, hyperglycemiaor insulin resistance for further study.

The invention discloses a novel synthesis method for preparing a chiral intermediate of omarigliptin. The method comprises the following steps: carrying out amidation, alder condensation, hydrazine hydrate condensation, rearrangement, Boc addition, ring opening and Grubbs catalyst ring formation on starting raw materials including crotonyl chloride and (S)-4-benzyl-2-oxazolidone and carrying out hydrolysis to obtain the chiral intermediate (IX). The preparation method disclosed by the invention has the advantages of relatively low cost, easiness for obtaining raw materials and relatively high yield, so that the preparation method is suitable for industrial production. The formula (IX) is shown in the description.

The invention discloses a compound or pharmaceutically acceptable salt thereof shown as a formula I (the formula l is shown in the following description), wherein R1, R2 and R3 are each independentlyselected from H or OCH3. In an in-vitro DDP-4 enzyme inhibition test, IC50 values of listed compounds to DDP-4 are all smaller than omarigliptin and Sitagliptin. The test shows that the compound provided by the invention has better DDP-4 inhibition activity and can be used for deeper study as a drug for treating and / or preventing non-insulin-dependent diabetes mellitus, hyperglycemia or insulin resistance.

The invention provides a preparation method of an alogliptin intermediate, comprising, raw material A 2-(2,5-difluorophenyl)-2-oxoethylcarbamate alkyl ester, and raw material B alkyl sulfonate Acid propargyl ester reaction, obtains product C 1-(2,5-difluorophenyl)-1-oxopent-4-yn-2-ylcarbamate alkyl ester. The present invention has a unique approach, selects a specific alogliptin intermediate as a research direction, provides an efficient process, and the one-step reaction yield can be as high as 96%.